Coinbase CEO Backs SEC Accredited Investor Reform 
US Dollar Near 18-Month High Ahead of Inflation Data 
PepsiCo Slashes Poppi Earnout Valuation as Growth Slows 
Epic Games Delays Disney Shooter, Shifts to AI-First Development 
Bank of America Predicts Yen Rebound as USD/JPY Faces Risks 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
Syndax Stock Drops 15% After Axatilimab Trial Failure 
Meta Launches Muse Wonder AI Models, Shares Rise 3.7% 
FAA Warns US Airlines Over Saudi Arabia Flight Risks 
Orsted to Take Full Ownership of UK Offshore Wind Farm for £15 Million 
Samsung, SK Hynix Shares Plunge as China Chip Competition Grows 
European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
US Stock Futures Rise as Oil Prices Fall Ahead of Q3 Earnings 
Oil Prices Surge Above $106 After Deadly Saudi Airport Attack 
Visa Wins China Approval to Prepare Domestic Payments Expansion 
Wall Street Ends Mixed as Investors Await CPI and Bank Earnings 
Oil Prices Rise as Houthi Attacks Threaten Middle East Supply 
Add as a preferred source on Google
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
